Filing Flows › Rigel Pharmaceuticals (RIGL) › Contract revenues from collaborations and other revenue
Rigel Pharmaceuticals (RIGL) Contract revenues from collaborations and other revenue by quarter
Rigel Pharmaceuticals' Contract revenues from collaborations and other revenue was $8.6M in Q3 2026 (third quarter 2026), +121% from Q1 2026. Over the last 4 quarters it ranged from $3.9M (Q1 2026) to $8.6M (Q3 2026).
| Quarter | Contract revenues from collaborations and other revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $8.6M | +121% | +59% |
| Q1 2026 | $3.9M | -5% | — |
| Q4 2025 | $4.1M | -24% | — |
| Q3 2025 | $5.4M | — | — |
Q3 2026 at a glance
Rigel Pharmaceuticals, Q3 2026: revenue $80.9M (+16% year over year), operating margin 21.1%, net earnings $13.2M, operating cash flow $34.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Rigel Pharmaceuticals' Contract revenues from collaborations and other revenue?
Rigel Pharmaceuticals' Contract revenues from collaborations and other revenue was $8.6M in Q3 2026 (third quarter 2026), +121% from Q1 2026.
How has Rigel Pharmaceuticals' Contract revenues from collaborations and other revenue changed?
Over the last 4 quarters it ranged from $3.9M (Q1 2026) to $8.6M (Q3 2026).